Drs. M. Ali Khan, Ajay Kuriyan, and Sarah Read discuss recent developments in intravitreal injectable drugs, including 8-mg aflibercept not approved by FDA, PDUFA date for on-label bevacizumab, and injections for dry AMD. They explore step therapy, biosimilars, and the impact on costs and access. They also cover treatment options and decision-making for AMD patients with geographic atrophy. A casual basketball conversation concludes the podcast.
